DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2012/0157405 A1 White, III (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2012/0157405 A1 White, III (43) Pub US 2012O157405A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0157405 A1 White, III (43) Pub. Date: Jun. 21, 2012 (54) METHODS AND COMPOSITIONS FOR THE A63L/488 (2006.01) TREATMENT OF "BURNING FEET A 6LX 3/59 (2006.01) SYNDROME" A63L/385 (2006.01) A6II 3/525 (2006.01) (76) Inventor: John B. White, III, Hurricane, WV (US) (52) U.S. Cl. ........... 514/52: 514/440, 514/276; 514/251: 514/89: 514/387: 514/249 (21) Appl. No.: 13/229,860 (57) ABSTRACT (22) Filed: Sep. 12, 2011 A composition for the treatment of “Burning Feet Syndrome' Related U.S. Application Data includes pantothenic acid or its analogs, or its derivatives, or its synonyms, alpha-lipoic acid or its analogs, or its deriva (63) Continuation-in-part of application No. 12/972.499. tives, or its synonyms, and L-arginine or its analogs, or its filed on Dec. 19, 2010. derivatives, or its synonyms. The composition may also include at least one Substance selected from the group con Publication Classification sisting of B1, B2, B3, B6, B7, B9, B12, Acetly-L-Carnitine, (51) Int. Cl. N-acetlycystein, Omega-3 fatty acids, Omega-6 fatty acids, A6 IK3I/7064 (2006.01) Vitamin E, and Taurine or any of their analogs, derivatives, or A6 IK3I/SI (2006.01) synonyms. The composition is used in a method for the treat A6IP 25/02 (2006.01) ing of “Burning Feet Syndrome' by administering to a human A6 IK3I/675 (2006.01) Such a composition. US 2012/O157405 A1 Jun. 21, 2012 METHODS AND COMPOSITIONS FOR THE for almost two centuries. “Burning Feet Syndrome' has TREATMENT OF "BURNING FEET received scant attention in the medical literature and has been SYNDROME" described only in anecdotal reports. There is no specific eti ology and it can occur as an isolated symptom or as a part of CROSS-REFERENCE TO RELATED a symptom complex in a variety of clinical settings. APPLICATION 0006 U.S. Pat. No. 7,803,790 to Chong, et al. relates to compounds and methods for treating pain and other condi 0001. This application is continuation-in-part of U.S. tions related to TRPV3. The TRPV3 antagonist of Chong, et patent application Ser. No. 12/972,499, filed Dec. 19, 2010, al. can be used as part of a prophylaxis or treatment for a the entire contents of which are incorporated herein by refer variety of disorders and conditions which include Grierson CCC. Gopalan syndrome (better known as burning feet syndrome). This patent discloses that, in Some instances, vitamin or min BACKGROUND OF THE INVENTION eral deficiencies may lead to ulcers or other sores in the 0002 “Burning Feet Syndrome,” also known as Gopalan's mouth. For example, deficiency in Vitamin C may lead to the Syndrome, is a neurological disorder characterized by Symp oral lesions characteristic of Scurvy. Deficiencies in vitamins toms of a burning sensation in the sole of the foot. The burning B1, B2, B6, or B12 may also lead to oral lesions. Additionally, tends to be more intense at night and may also involve the deficiencies in Zinc, folic acid iron, selenium or calcium may hands. Possible causes include causalgia from injury to the lead to oral lesions. The TRPV3 inhibitors of Chong, et al. can sciatic nerve, degeneration of the spinal cord, and polyneur be administered with vitamins and derivatives thereof includ opathy. The condition is also associated with diabetes melli ing Vitamin A, AScorbic acid (Vitamin C), alpha-tocopherol tus, kidney disease, and a B vitamin deficiency. (Vitamin E), 7-dehydrocholesterol (Vitamin D), Vitamin K. 0003 Causalgia is defined as burning pain, often with Alpha-Lipoic Acid, lipid soluble anti-oxidants, and the like. trophic skin changes, due to peripheral nerve injury (i.e. 0007 U.S. Pat. No. 7,671,061 to Moran, et al. relates to Injury to sciatic nerve, degeneration of the spinal cord). Poly compounds and methods for treating pain, incontinence, and neuropathy is defined as a condition in which many peripheral other conditions. The TRPV1 antagonist of Moran, et al. can nerves are afflicted with a disorder. Therefore, the “burning be used as part of a prophylaxis or treatment for a variety of sensation' is a symptom caused by polyneuropathy disorders. disorders and conditions which include Grierson-Gopalan These disorders may be acute or chronic. Acute polyneuropa Syndrome (better known as “Burning Feet Syndrome').). thy has many causes: infections involving a toxin produced by This patent also discloses that, in some instances, vitamin or bacteria, as occurs in diphtheria, an autoimmune reaction as mineral deficiencies may lead to ulcers or other Sores in the occurs in Guillain-Barre Syndrome, toxic Substances, includ mouth. For example, deficiency in Vitamin C may lead to the ing heavy metals such as lead and mercury, drugs, including oral lesions characteristic of scurvy, deficiencies in vitamins the anticonvulsant phenytoin, some antibiotics (such as B1, B2, B6, or B12 may also lead to oral lesions and, addi chloramphenicol, nitrofurantoin, and Sulfonamides), some tionally, deficiencies in Zinc, folic acid iron, selenium or chemotherapy drugs (such as vinblastine and Vincristine), calcium may lead to oral lesions. The TRPA 1 inhibitors of and some sedatives (such as barbital and hexobarbital), and Moran et al. can also be administered with vitamins and cancer. Such as multiple myeloma, which damages nerves derivatives thereof including Vitamin A, ascorbic acid (vita directly invading or putting pressure on them or by triggering min C), alpha-tocopherol (Vitamin E), 7-dehydrocholesterol an autoimmune reaction. (D), Vitamin K, Alpha-lipoic Acid, lipid soluble anti-oxi 0004 Chronic polyneuropathy has many causes: diabetes, dants, and the like. excessive use of alcohol, nutritional deficiencies (such as 0008 U.S. Pat. No. 7,115,286 to Meredith concerns meth thiamin deficiency, a uncommon cause in the United States, ods and compositions to inhibit insects from biting a Subject. except among alcoholics who are malnourished), anemia due In preferred embodiments, the compositions may be admin to vitamin B12 deficiency (pernicious anemia), an underac istered orally, for example using a spray bottle to deliver to the tive thyroid gland (hypothyroidism), liver failure, kidney fail mouth. The compositions may include one or more herbs ure, certain cancers, such as lung cancer, and Vitamin B6 selected from the group consisting of rice bran, peppermint, (pyridoxine) taken in excessive amounts. Specifically, Pan barely grass. lobelia; chlorella watercress, alfalfa, and parsley tothenic acid deficiency in humans has been induced experi and one or more vitamins selected from the group consistent mentally by administering a Pantothenic acid antagonist of thiamin (B1), riboflavin (B-2), niacin (B3), Pantothenic together with a Pantothenic acid deficient diet. Participants in acid (B5), pyridoxine (B6), folic acid (B9), cyanocobalamin this experiment complained of headache, fatigue, insomnia, (B12), choline, inositol, d-biotin, para-amino-benzoic acid, intestinal disturbances, and numbness and tingling of their and lecithin. hands and feet. Symptoms of deficiency are similar to other 0009 U.S. Pat. Nos. 7,569,384 and 7,521,424 Rosen et al. vitamin B deficiencies. It has been noted that painful burning encompass albumin fusion proteins. These patents disclose sensations of the feet were reported in tests conducted on that nucleic acid molecules encoding the albumin fusion pro volunteers. Deficiency of Pantothenic acid may explain simi teins of the invention are also encompassed by the invention, lar sensations reported in malnourished prisoners of war. as are vectors containing these nucleic acids, host cell trans 0005 Burning is a sensation described as a paresthesia. formed with these nucleic acids vectors, and methods of Paresthesias are defined as abnormal sensations experienced making the albuminfusion proteins of the invention and using in the absence of specific stimuli. These sensations are usu these nucleic acids, vectors, and/or host cells. ally described as burning, tingling or numb feelings, although 0010 Kindermann et al. in the titled article “New Drug they may be described as feelings of cold, warmth, prickling, Combination for Treating Polyneuropathy' observed that pins and needles, skin crawling or itching. Burning pain in the human Subjects that were pretreated for symptoms of poly feet has been known to occur as a distinct clinical symptom neuropathy with alpha-lipoic acid showed an additional US 2012/O157405 A1 Jun. 21, 2012 improvement with a combination of Pantothenic acid. Alpha Additionally, the combination improves the parathesia burn lipoic acid was used in dosages of 300 milligrams/day and ing of “Burning Feet Syndrome more effectively than one 600 milligrams/day. As Pantothenic acid was added to the lone Substance. combination additional improvements for the symptoms 0014 Applicant has also found, unexpectedly, that the were noted in polyneuropathy (diabetic polyneuropathy, addition of one or more of the following B1, B2, B3, B6, B7, alcohol induced polyneuropathy, and unknown causes of B9, B12, Acetyl-L-Carnitine, N-acetycysteine, Curcumin, polyneuropathy). Noted was as Pantothenic acid dose was Omega-3 fatty acids, Omega-6 fatty acids, vitamin E, and increased to the combination the symptoms were noted to Taurine, will increase the efficacy, with no increased chance improve in 28 of 33 (84.8%) of the human subjects. Also of adverse reaction(s). noted was that both Alpha-lipoic acid and Pantothenic acid 0015. In the United States, symptomatic treatments for have a different implication in the pyruvate metabolism and these parethesias include tricyclic antidepressants (TCAS), therefore, this is why the combination is more effective than selective serotonin reuptake inhibitors, serotonin nor-epi just one substance. At this level, the pyruvate metabolism is nephrine reuptake inhibitors, calcium-channel blockers, dependent on alpha-lipoic acid and pantothenic acid is a Sodium channel blockers, topical capsaicin, opioids, anticon precursor for acetylcholine production (essential for periph Vulsants.
Load more

Recommended publications
  • Evaluation of Symptom Heterogeneity in Neuropathic Pain Using Assessments of Sensory Functions
    Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics Evaluation of Symptom Heterogeneity in Neuropathic Pain Using Assessments of Sensory Functions Kathrin Arning and Ralf Baron Division of Neurological Pain Research and Therapy, Department of Neurology, Christian-Albrechts-Universität Kiel, Germany Summary: Classification of neuropathic pain has been based can be elucidated in each patient. Moreover, in questionnaires on disease entities, anatomical localization, or histological ob- the verbal descriptors can depict the quality and intensity of the servations. Over the past decade, there has been an explosion in individual pain. The approach of classifying and subgrouping our understanding of the basic mechanisms of neuropathic pain. patients with neuropathic pain on the basis of symptoms or The exciting advances in basic science are paralleled by the signs opens up new possibilities for stratifying patients in clin- recognition from clinical investigations that neuropathic pain is ical trials. First, in clinical proof-of-concept trials the study not a monolithic entity, but instead presents as a composite of population can be enriched prospectively on the basis of entry pain and other sensory symptoms. Attempts are under way to criteria defined a priori. This enrichment with patients who supplement the traditional classification with a classification potentially require a specific treatment should increase the like- that links pain and sensory symptoms with neurobiological lihood for positive trial outcomes. Second, in clinical practice it mechanisms. This mechanism- or symptom-based classifica- becomes possible to establish an individualized therapy—that tion takes both negative and positive sensory symptoms into is, to identify the particular patients who require a specific account.
    [Show full text]
  • Restless Legs Syndrome in Adults
    The night time hustle: managing restless legs syndrome in adults 18 BPJ Issue 49 Restless legs syndrome is a common condition that Approximately four in five people with restless legs syndrome can significantly affect a patient’s quality of life. It also experience periodic limb movement of sleep (PLMS). is a neurological disorder, which can be diagnosed This is characterised by involuntary leg movement while the on the basis of the patient’s description of their person is asleep. The condition can cause repeated waking and poor sleep quality. The presence of PLMS in a person symptoms. Lifestyle modification is the mainstay with restless legs syndrome is likely to increase the severity of of treatment for patients with mild or infrequent impact on the person’s quality of life through the combination symptoms. Pharmacological treatments, starting of delayed sleep onset from restless legs syndrome and poor with dopamine agonists, should be reserved for quality sleep from PLMS. people with more severe symptoms. A diagnosis is made based on description of What is restless legs syndrome? symptoms Restless legs syndrome is a neurological disorder characterised There is no specific examination or test that will confirm a by throbbing, pulling, creeping or other unpleasant sensations diagnosis of restless legs syndrome. The patient’s description in the legs and an uncontrollable, usually overwhelming, urge of their symptoms, combined with a brief history, is sufficient to move them. Symptoms occur primarily in the evening when to make a diagnosis. a person is relaxing, and can increase in severity throughout the night. Both legs may be affected or one may be worse than The diagnostic criteria for restless legs syndrome is a history the other.
    [Show full text]
  • Siegenthaler, Differential Diagnosis in Internal Medicine (ISBN9783131421418), © 2007 Georg Thieme Verlag Index
    Index Notes: Please note that entries in bold and italics represent tables and figures respectively A parapharyngeal space, 479 acromegaly, 81, 82, 743−744 acute renal failure (ARF), 852−857 spleen, 151 hands, 90 angiography, 854 Abciximab, thrombocytopenia, teeth, 212 hypertension, 738 causes, 853 459 tuberculous paravertebral, skin changes, 66 classification, 852 abdomen 597−599 ACTH-dependent Cushing definition, 852 acute see acute abdomen absolute pupillary areflexia, 97 syndrome, 742 diagnostic procedure, 855−857 angina, mesenteric infarction, Abt−Letterer−Siwe disease, 445 ACTH-independent Cushing blood analysis, 856 266 Acanthamoeba infection, syndrome, 742−743 glomerular filtration rate, 855 blood vessels, polyarteritis meningitis, 135 Actinomyces infection see main laboratory nodosa, 179 acanthocytes actinomycosis investigations, 856 pain see abdominal pain liver cirrhosis, 398 Actinomyces israelii, 131 physical examination, physical examination, 30−31 urinary sediment analysis, 847, actinomycosis, 71, 526 855−856 pleural effusion, 248 848 neck swelling, 131 radiologic examinations, 857 ultrasound, secondary acanthocytosis, 417 activated partial thromboplastin renal biopsy, 857 hypertension, 733 acanthosis nigricans, 55, 55 time (aPTT), 452, 1052−1053 urinalysis, 856 abdominal organs, nervous accelerated junctional rhythms, acute abdomen, 257−259 differential diagnosis, 855, system, 256 719 causes, 257, 257−258 855−857 abdominal pain acetaminophen chronic renal failure, 861 acute tubular necrosis vs., acute, 257−273 analgesic
    [Show full text]
  • Small Fiber Neuropathy and Sodium Channels : a Paradigm Shift
    Small fiber neuropathy and sodium channels : a paradigm shift Citation for published version (APA): Hoeijmakers, J. G. J. (2014). Small fiber neuropathy and sodium channels : a paradigm shift. Datawyse / Universitaire Pers Maastricht. https://doi.org/10.26481/dis.20140214jh Document status and date: Published: 01/01/2014 DOI: 10.26481/dis.20140214jh Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.
    [Show full text]
  • Gain of Function Nav1.7 Mutations in Idiopathic Small Fiber Neuropathy
    ORIGINAL ARTICLE Gain of Function NaV1.7 Mutations in Idiopathic Small Fiber Neuropathy Catharina G. Faber, MD, PhD,1 Janneke G. J. Hoeijmakers, MD,1 Hye-Sook Ahn, PhD,2,3 Xiaoyang Cheng, PhD,2,3 Chongyang Han, PhD,2,3 Jin-Sung Choi, PhD,2,3* Mark Estacion, PhD,2,3 Giuseppe Lauria, MD, PhD,4 Els K. Vanhoutte, MD,1 Monique M. Gerrits, PhD,5 Sulayman Dib-Hajj, PhD,2,3 Joost P. H. Drenth, MD, PhD,6 Stephen G. Waxman, MD, PhD,2,3 and Ingemar S. J. Merkies, MD, PhD1,7 Objective: Small nerve fiber neuropathy (SFN) often occurs without apparent cause, but no systematic genetic studies have been performed in patients with idiopathic SFN (I-SFN). We sought to identify a genetic basis for I-SFN by screening patients with biopsy-confirmed idiopathic SFN for mutations in the SCN9A gene, encoding voltage- gated sodium channel NaV1.7, which is preferentially expressed in small diameter peripheral axons. Methods: Patients referred with possible I-SFN, who met the criteria of 2 SFN-related symptoms, normal strength, tendon reflexes, vibration sense, and nerve conduction studies, and reduced intraepidermal nerve fiber density (IENFD) plus abnormal quantitative sensory testing (QST) and no underlying etiology for SFN, were assessed clinically and by screening of SCN9A for mutations and functional analyses. Results: Twenty-eight patients who met stringent criteria for I-SFN including abnormal IENFD and QST underwent SCN9A gene analyses. Of these 28 patients with biopsy-confirmed I-SFN, 8 were found to carry novel mutations in SCN9A. Functional analysis revealed multiple gain of function changes in the mutant channels; each of the mutations rendered dorsal root ganglion neurons hyperexcitable.
    [Show full text]
  • Erythromelalgia - an Uncommon Challenging Entity
    Data da submissão: 6 de Março de 2021 CARTA AO EDITOR Data da aprovação: 17 de Março de 2021 ERYTHROMELALGIA - AN UNCOMMON CHALLENGING ENTITY ERITROMELALGIA - UMA ENTIDADE DESAFIADORA INCOMUM Vitorino Modesto dos Santos, Laura Campos Modesto DOI - 10.5935/2236-5117.2021v58a44 small fiber neuropathies, neurofibromatosis, and Vitorino Modesto dos Santos – Armed Forces Hospital and Catholic University, multiple sclerosis), diabetes gout, astrocytoma, Brasília-DF, Brazil, Internal Medicine - Brasília - DF, Brasil. colon cancer, thyroid cancer, and breast cancer, Laura Campos Modesto – University Center of Brasília (Uniceub), Brasília-DF, medications (bromocriptine, nifedipine, verapamil, Brazil, Medical Course - Brasília - DF, Brasil. topical isopropanol, pergolide, and simvastatin), arterial hypertension, venous insufficiency, pregnancy, Correspondência: Vitorino Modesto dos Santos. Quadra SMPW 1-5 Quadra 14 Conjunto 2, Lote 7, Casa A, Park Way, Brasília - DF, Brasil alcohol abuse, and mercury poisoning. The common - CEP: 71741402 hypothesis for both types of EM is that symptoms occur Internet: [email protected] by skin hypoxia due to increased arteriovenous shunting and imbalance between thermoregulatory and nutritive perfusion.1 The symptoms of EM typically appear under influence of warm or exercise and improve by cooling Conflito de interesses: não existem conflitos de interesse. the affected regions; the episodes commonly occur at night periods and the affected regions characteristically remain normal between the acute crises.
    [Show full text]
  • National Consensus on Diagnosis and Treatment of Pain of Neurological Origin
    National Consensus on Diagnosis and Treatment of Pain of Neurological Origin Under the supervision of Acad. Prof. I. Milanov, MD, PhD, DSc. By initiative of the Bulgarian Headache and Pain Association 3 Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Classification By its duration pain is classified as acute and chronic. Acute pain is a symptom, chronic pain is a disease. Acute pain is related to clearly identified tissue injury and lasts no more than 1 month from its onset. It is protective and gradually resolves as the injured tissues heal, when the environment surrounding the nociceptors is normalized and their hyperactivity resolved. Chronic pain persists for more than 3 months. It is caused by tissue damage but continues even after the causative lesion heals. It is not due to activation of nociceptors and has no protective effect. According to the underlying pathophysiological mechanisms pain is classified as nociceptive or neuropathic. The combination of both types (mixed) pain is common. According to its anatomical location pain is classified as head, face and mouth pain; cervical pain; pain in shoulders and arms; thoracic; abdominal; lumbar pain; pain in lower limbs; pelvic; anal, perianal and genital pain. Nociceptive pain It is caused by injury to any organ or system other than the nervous system, and its diagnosis and treatment is associated with a number of medical specialties. It is subdivided into physiological nociceptive pain, caused by temporary dysfunction (cramps, colics), and pathological nociceptive pain, caused by tissue injury. Neuropathic pain It is pain caused by dysfunction, lesion or disease directly affecting the somatosensory nervous system.
    [Show full text]
  • Vol 27, No 05 | May 2013
    PEDIATRIC NEUROLOGY BRIEFS A MONTHLY JOURNAL REVIEW J. GORDON MILLICHAP, M.D., F.R.C.P., EDITOR Vol. 27, No. 5 May 2013 NEUROMUSCULAR DISORDERS SMALL-FIBER POLYNEUROPATHY AND PAIN SYNDROMES Investigators at the Massachusetts General Hospital, Boston, MA, tested the hypothesis that acquired small-fiber polyneuropathy (SFPN) contributes to unexplained widespread pain syndromes in children and adolescents. Medical records of 41 consecutive patients were analyzed for objective diagnostic test data for SFPN. These included skin biopsy, nerve biopsy, and autonomic function testing, plus histories, symptoms and signs, and treatments. Healthy matched volunteers acted as normal controls for SFPN tests. In this polyethnic patient sample, age at illness onset averaged 12.3 +/- 5.7 years; 73% were female, 68% chronically disabled, and 68% had been hospitalized. Objective diagnostic test results were definite for SFPN in 59%, probable in 17%, and possible in 22%. Only 1 had normal SFPN test results. Somatic complaints other than pain were reported in 98% patients and were consistent with SFPN dysautonomia (90% cardiovascular, 82% gastrointestinal, and 34% urological). Chronic fatigue was reported in 83% and chronic headache in 63%. Neurological examinations identified reduced sensation in 68% and vasomotor abnormalities in 55%, including erythromelalgia in 23%. Tests for causality of pain revealed only a history of autoimmune disease elicited in 33% and serologic markers of disordered immunity in 89%. Treatment with corticosteroids and/or IV immunoglobulin benefited 80% of patients (12/15), both objectively and subjectively. (Oaklander AL, Klein MM. Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes. Pediatrics 2013 Apr;131(4):e1091-e1100).
    [Show full text]
  • MAYO CLINIC ESSENTIAL NEUROLOGY Covers the Full Scope of Neurology by Combining a Focused Need-To-Know Format with Core Knowledge Andrea C
    A Concise and Succinct Guide to Neurology! Illustrated in Full Color This full-color guide to the essentials of neurology provides Adams Mayo Clinic practicing clinicians and students with one of the most focused Throughout presentations in the field today. Essential Neurology MAYO CLINIC ESSENTIAL NEUROLOGY covers the full scope of neurology by combining a focused need-to-know format with core knowledge Andrea C. Adams, MD as well as diagnosis and treatment guidelines. More than 75 color illustrations and numerous therapeutic tables help you diagnose, treat, and manage the Clinic Essential Neurology Mayo most commonly encountered neurologic problems. TOPICS INCLUDE: • The Neurologic Examination • Cognitive Loss • Diagnostic Tests • Spells • Headache • Pain • Spine and Limb Pain • Cerebrovascular Disease • Dizziness • Movement Disorders • Sensory Loss and Paresthesias • Immune and Infectious Diseases • Weakness • Neuro-oncology The perfect introduction for medical students, and a great daily reference for residents and clinicians, Mayo Clinic Essential Neurology’s current and consultative full-color format provides a fresh alternative to the current library of neurology references in print today. ABOUT THE AUTHOR ANDREA C. ADAMS, M.D., is a Consultant, Department of Neurology, Mayo Clinic, Rochester, Minnesota, and Assistant Professor of Neurology, College of Medicine, Mayo Clinic. MAYO CLINIC SCIENTIFIC PRESS Mayo Clinic Essential Neurology Andrea C. Adams, MD Mayo Clinic Essential Neurology Andrea C. Adams, MD Consultant, Department of Neurology, Mayo Clinic, Rochester, Minnesota; Assistant Professor of Neurology, College of Medicine, Mayo Clinic MAYO CLINIC SCIENTIFIC PRESS AND INFORMA HEALTHCARE USA, INC ISBN-13 9781420079739 The triple-shield Mayo logo and the words MAYO, MAYO CLINIC, and MAYO CLINIC SCIENTIFIC PRESS are marks of Mayo Foundation for Medical Education and Research.
    [Show full text]
  • Copyrighted Material
    1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff
    [Show full text]
  • The Night Time Hustle: Managing Restless Legs Syndrome in Adults
    The night time hustle: managing restless legs syndrome in adults 18 Restless legs syndrome is a common condition that Approximately four in five people with restless legs syndrome can significantly affect a patient’s quality of life. It also experience periodic limb movement of sleep (PLMS). is a neurological disorder, which can be diagnosed This is characterised by involuntary leg movement while the on the basis of the patient’s description of their person is asleep. The condition can cause repeated waking and poor sleep quality. The presence of PLMS in a person symptoms. Lifestyle modification is the mainstay with restless legs syndrome is likely to increase the severity of of treatment for patients with mild or infrequent impact on the person’s quality of life through the combination symptoms. Pharmacological treatments, starting of delayed sleep onset from restless legs syndrome and poor with dopamine agonists, should be reserved for quality sleep from PLMS. people with more severe symptoms. A diagnosis is made based on description of What is restless legs syndrome? symptoms Restless legs syndrome is a neurological disorder characterised There is no specific examination or test that will confirm a by throbbing, pulling, creeping or other unpleasant sensations diagnosis of restless legs syndrome. The patient’s description in the legs and an uncontrollable, usually overwhelming, urge of their symptoms, combined with a brief history, is sufficient to move them. Symptoms occur primarily in the evening when to make a diagnosis. a person is relaxing, and can increase in severity throughout the night. Both legs may be affected or one may be worse than The diagnostic criteria for restless legs syndrome is a history the other.
    [Show full text]
  • Burning Feet Syndrome a Clinical Review
    CLINICAL PRACTICE: Clinical review Burning feet syndrome A clinical review Ravinder P S Makkar, MD, is Medical Advisor, Department of Medical Assistance, International SOS, New Delhi, India. Anju Arora, MD, is attending physician, Department of Medicine, Sitaram Bhartia Institute of Science and Research, New Delhi, India. Amitabh Monga, MD, is attending physician, Department of Medicine, Sitaram Bhartia Institute of Science and Research, New Delhi, India. Ajay Kr Gupta, MD, is attending physician, Department of Medicine, Sitaram Bhartia Institute of Science and Research, New Delhi, India. Surabhi Mukhopadhyay, MD, is attending physician Department of Medicine, Sitaram Bhartia Institute of Science and Research, New Delhi, India. BACKGROUND Burning pain in the feet has been known to occur as a distinct clinical symptom for almost two centuries. Despite being a common and fascinating clinical entity, this syndrome has received scant attention in the medical literature and has been described only in anecdotal reports. OBJECTIVE This article describes and discusses the various aspects of this intriguing syndrome. DISCUSSION Burning feet syndrome (BFS) is a common disorder especially among the elderly and is frequently encountered in general practice. There is no specific aetiology and it can occur as an isolated symptom or as part of a symptom complex in a variety of clinical settings. In contrast to the presence of distressing subjective symptoms, the physical examination is marked by a paucity of objective signs. The pathophysiology of BFS is not very clear and treatment varies depending on the aetiology. urning feet syndrome (BFS), which is be divided into the following categories ciency related neuropathy before frank Bcharacterised by a sensation of (Table 1).
    [Show full text]